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Background
Hepatitis C is an infective liver disease affecting globally more than 71 million people 
and causing 399,000 deaths each year [1]. The disease burden encouraged the World Health 
Organization (WHO) to launch a program aiming at eliminating Hepatitis C Virus (HCV) by 
2030 [2].
Although 15-45% [1] of infected people can recover within 6 months of infection without 
any treatment, the chronic infection caused by HCV often leads to the development of cirrho-
sis, hepatocellular carcinoma (HCC) and several other comorbidities that complicate patient 
conditions.
In Italy the Italian Medicines Agency (AIFA) estimates that there are up to 300,000 infect-
ed HCV patients (0.5% prevalence). The mortality rate of HCV-related diseases still accounts 
for 10,000 cases a year [3].
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aBstract
BACKGROUND: Access to Directly Acting Antivirals (DAAs) for Hepatitis C Virus (HCV) treatment in Italy was initially 
restricted to severe patients. In 2017, AIFA expanded access to all patients, to achieve elimination by 2030.
AIM: To investigate the impact of different hospitals’ organizational models on elimination timing, treatment capacity and 
direct costs.
METHODS: Most Regional healthcare systems in Italy deploy a Center of Excellence (CoE) organizational model, where 
patients are referred to a single major hospital in the area, which is the only one that can prescribe and deliver DAAs. The 
study was conducted at Bergamo’s (Lombardy, Italy) Papa Giovanni XXIII hospital (PG-23), which deploys a Hub&Spoke 
model: the Hub (PG-23) prescribes and delivers DAAs while Spokes (four smaller hospitals) can only prescribe them. The 
study compares the two models (CoE vs. H&S). Patient journey and workloads were mapped and quantified through inter-
views with hospital stakeholders. Cost data were collected through the hospital’s IT system; the sample comprised 2,277 
HCV patients, over one year.
RESULTS: The study calculated the average cost to treat HCV patients (~ € 1,470 per patient). Key cost drivers are lab tests 
(60%) and specialist visits (30%). Over one year, H&S can treat 68% more patients than CoE. As deferred patients absorb 
up to 40% of total costs, the “Optimized” model was designed by streamlining specialists’ visits and involving general 
practitioners during follow-up. “Optimized” model increases treatment capacity and reduces costs of deferred patients by 
72% vs CoE.
CONCLUSION: The study demonstrates the importance of organizational models in efficiently achieving 2030 elimina-
tion. 
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For a long time, HCV has been difficult to treat and the only available pharmacological thera-
pies, interferon and ribavirin, did not ensure full patient recovery nor absence of side-effects. 
Starting in 2011, Directly Acting Antivirals (DAAs) have been introduced in Italy, representing 
an initial step towards virus elimination. The first generation of DAAs (telaprevir and bocepre-
vir) reached a 75% of sustained virologic response (SVR) in clinical trials [4,5]. Second genera-
tion of DAAs and their combinations (sofosbuvir, simeprevir, daclatasvir, ledipasvir, ombitasvir/
paritaprevir/ritonavir, dasabuvir, elbasvir/grazoprevir) significantly increased SVR up to 95% 
and showed rare side-effects [6]. The wave of third generation of DAAs (sofosbuvir/velpatasvir, 
glecaprevir/pibrentasvir), introduced in 2016/2017, represented a further improvement in treat-
ment: new pangenotypic drugs treating patients with a SVR > 97.5% in less than 12 weeks [6].
However, access to DAAs in Italy was initially limited by AIFA to patients presenting 
the most severe levels of the disease and with life-threatening conditions (i.e., fibrosis higher 
than 3 or patients with critical extra-hepatic complications). On top of that, only a selected 
number of hospitals, qualifying as Centre of Excellence (CoE), were allowed to prescribe 
and distribute DAAs [7]. The decisions to limit both access criteria and prescribing centers 
were taken to ensure treatment economic sustainability, considering the high HCV prevalence 
across the Country and the substantial impact of DAA costs on Italian National Healthcare 
System expenditure [8].
Following the introduction of DAAs, Lombardy’s Healthcare System (one of the 21 dif-
ferent Regional Healthcare Systems in Italy) developed a new integrated care pathway [9] for 
HCV, explicitly calling for key organizational requirements a hospital would need to meet in 
order to be qualified as a CoE (refer to Table I).
ASST-Papa Giovanni XXIII (PG-23) qualified as CoE and started dispensing DAAs to 
HCV patients in the Bergamo area (Lombardy, Italy), commencing from mid-2015. During 
this period, in compliance with regional regulation and aiming to increase treatment capacity 
as well as to ensure treatment continuity for patients, the PG-23 designed and implemented a 
new Hub&Spoke organizational model comprising the PG-23 itself, as the Hub and the only 
hospital in the area authorized as a DAA prescriber and distributor, and other six smaller hos-
pitals as Spokes. The introduction of the Spokes not only allowed to increase the number of 
access points, but also offered the opportunity for existing patients to be referred to the center 
where they had received previous treatments (e.g. interferon and ribavirin) and for new ones 
to be directly referred to the closest hospital. Notwithstanding the efforts of healthcare pro-
viders to improve treatment access, and as a consequence of AIFA’s access policy, a relevant 
number of HCV affected patients could not be treated with DAAs in Italy. Finally, as of mid-
2017, AIFA expanded access to DAAs for all HCV patients [10]; the rationale behind such de-
cision was achieving disease elimination in 2030, by treating about 80,000 patients per year.
Considering that extending HCV treatment to patients in any fibrosis stage has been 
proved to improve health outcomes and is cost-effective [11], is now pivotal to understand 
what is the organization model able to accelerate access to treatment as well as ensuring its 
economic sustainability.
The study aim was therefore threefold:
1. Investigate the Hub&Spoke organizational model deployed by PG-23 and assess its per-
formance in terms of HCV patient treatment capacity and direct hospital costs.
Minimum requirement Highly recommended
 • A multidisciplinary team made up by a liver disease expert 
(gastroenterology, infectious disease, general medicine), a 
pathologist and a dedicated nurse. All team members must 
be skilled in viral hepatitis diseases
 • A defined team coordinator
 • A nurse skilled in patient education and treatment 
management
 • Current management of at least 500 hepatic patients
 • A radiology unit
 • A digestive endoscopy unit
 • A serology laboratory
 • A day hospital service for hepatic patients
 • A pharmacy to dispense DAA, provide counseling in 
compliance with AIFA requirements
 • An integrated path with the regional transplant network
 • An access to a multidisciplinary day hospital to diagnose and 
treat hepatic patients
 • Clinical research activities
 • A virology laboratory
 • A laboratory specialized in drugs serum level monitoring
Table i. Key organizational characteristics that a HCV Centre of Excellence must have/ensure
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2. Identify areas of improvement in the organizational model currently deployed by PG-
23 and design an “optimized” organizational model improving the performance on the 
Hub&Spoke one.
3. Compare three different organizational models (CoE, Hub&Spoke, “optimized”) to un-
derstand their impact on elimination timing and cost effectiveness, with regards to AIFA’s 
new access criteria.
Methods
study Design
Study design consists of four main steps. Firstly, patient journey was mapped. We em-
ployed a swim lane chart approach to capture in detail key activities and interactions among 
the involved hospital stakeholders in HCV DAA patient journey.
Secondly, we quantified workloads for each activity of the journey performed by hospital 
stakeholders within PG-23 Hub&Spoke organization. Workload data were collected through 
24 interviews with hospital stakeholders involved in the patient journey (48% of total), in-
cluding:
 - Specialists (hepatologists and infectious diseases specialists);
 - Nurses;
 - Psychologists/psychiatrists;
 - Pharmacists and pharmacy assistants;
 - Laboratory technicians and directors.
Through interviews, we identified key improvement opportunities in the current organi-
zational model. Improvement opportunities were used to design a new “optimized” model, 
aiming to improve patient’s access to treatment.
Thirdly, we collected all relevant data input needed to quantify patient journey direct 
costs. Cost data were collected through PG-23 data owners (e.g. Controlling Department) 
while we leverage on an existing Lombardy Regional database to collect historical patients 
related information (e.g. DAA treatment period, genotype, fibrosis).
Finally, a parametric model was developed to assess the impact of the three organization 
models (CoE, Hub&Spoke, “optimized”) on elimination timing, treatment capacity and direct 
costs. 
study Population
Data sample included patients treated over one year (June 30th 2015 - June 30th 2016) in 
any of the seven hospitals part of PG-23’s Hub&Spoke organization:
1. ASST Ospedale Papa Giovanni XXIII (PG-23);
2. ASST-Bergamo Est (Bolognini, Seriate);
3. ASST-Bergamo Est (M.O.A. Locatelli, Piario);
4. ASST-Bergamo Ovest (A.O. S. Giovanni Bianco, Treviglio);
5. ASST-Bergamo Ovest (Ospedale “Treviglio-Caravaggio”, Treviglio);
6. Policlinico Ponte San Pietro;
7. Policlinico San Marco.
All patients were either HCV mono-infected, or HBV co-infected. The HBV coinfection 
had no impact on the HCV patient journey. Only patients treated with DAAs were included in 
study population (> 98% of all HCV patients). Data sample was extracted from a Lombardy 
Health Service database.
Patient data included clinical and general information such as genotype, fibrosis, hospital 
name, type and length of therapy, presence of co-morbidities.
We collected specific comorbidities data for HCV patients treated by the gastroenterol-
ogy unit of PG-23 (321 patients out of 579 patients treated in total by all five hospitals). The 
comorbidity distribution of the sub-sample was then applied to the wider study population.
New AIFA Access Criteria
All patients in the study population were eligible to DAA treatment according to AIFA 
access criteria in place until March 31th, 2017.
From March 31st, 2017, AIFA released 11 new access criteria that extended the access of 
treatment to all HCV patients, regardless of fibrosis level or other clinical parameters [12]. 
New access criteria were used in the parametric model to simulate the expansion of patient 
population eligible for DAA treatments.
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Deferred and Stand-by Patient Sample
On top of treated patients (i.e., patients who received DAA treatment in the study time-
frame), this study analyzed two additional groups of patients:
1. Deferred patients: patients who met AIFA access criteria in place before March 31st, 2017 
but could not receive treatment immediately, and were added to the waiting list;
2. Stand-by patients: patients who did not meet AIFA access criteria in place before March 
31st, 2017; F0-F1-F2 patients represent most of this group.
The number of deferred patients was calculated using Bergamo Hub&Spoke’s actual wait-
ing list as of January 2017. The number of stand-by patients was estimated through interviews 
with PG-23’s specialists and was based on their experience in the diagnosis phase of the 
patient journey.
We did not consider currently undiagnosed patients in the study, as we did not explore any 
relationship between them and the hospital’s organizational model.
Direct Hospital Costs
Direct hospital costs were calculated using four types of data:
1. Internal cost (in €) per hour of each stakeholder involved in the HCV patient journey;
2. Internal cost (in €) of each microbiology and virology test, including lab equipment;
3. Internal cost (in €) of Fibroscan testing;
4. Workload (in minutes) for each hospital stakeholder and each activity of the HCV patient 
journey.
Analysis did not include general&administative hospital costs, additional costs for pa-
tients resistant to DAA treatment (< 5% of patient population) and cost of HCV reinfection. 
Direct hospital costs also did not include the cost of purchasing DAA drugs, which are fully 
reimbursed by the Healthcare System.
Laboratory costs included cost per kit, supplementary disposables and equipment amor-
tization.
Organizational Models
The study analyzed three different organizational models: CoE, Hub&Spoke and “opti-
mized” model.
Center of Excellence (CoE)
CoE is the model originally designed by Lombardy Health Care system, where patients 
are referred to a single major hospital in the area, the only one authorized to prescribe and 
distribute DAAs (Table I). Patients can access the CoE through multiple access points (e.g. 
Gastroenterology units, Infectious disease units, General medicine, etc.) in the area.
Although the model ensures the delivery of standardized diagnostic/therapeutic flow in 
the area, it can limit continuity of treatment. Indeed, patients who were already enrolled 
for a previous HCV treatment (i.e., with interferon and ribavirin) in a different hospital 
than the CoE need to move to the CoE to receive DAA treatment, thus generally increasing 
logistical costs and time spent by patients and caregivers. Moreover, specialists and other 
stakeholders employed at non-CoE hospitals in the area are not adding to HCV treatment 
capacity. CoE analysis in the parametric model was performed assuming PG-23 as a stand-
alone center.
Hub&Spoke
Hub&Spoke is the model implemented by PG-23 and Bergamo-area hospitals, where the 
Hub (PG-23) is the only hospital in the network authorized as a DAA prescriber and distribu-
tor. The other four smaller hospitals deploy specialists, formally employed by the Hub, who 
can prescribe DAA treatments.
The model involves a total of 48 clinical stakeholders in HCV care: 24 specialists, 6 nurs-
es, 1 psychologist, 1 psychiatrist, 3 pharmacists, 1 pharmacist assistant, 2 laboratory directors 
and 10 laboratory technicians.
Hub&Spoke provides patients with widespread accessibility, ensuring treatment continu-
ity. The continuity is applied to all patients, including those previously enrolled in Spoke 
centers (e.g. patients treated with interferon and ribavirin). Each center is able to prescribe 
DAAs; however, supply and dispensing are managed centrally by the Hub.
Four nurses, available in three out of the five hospitals of the Hub&Spoke network, were 
dedicated to the HCV treatment. Nurses support specialists for patients scheduling, document 
preparation, medical services dispensing and patient’s condition monitoring.
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“Optimized”
Three optimization opportunities were identified and selected to design the “optimized” 
model:
1. Involvement of GPs to follow-up on patients without comorbidities. It was observed that 
the effectiveness/SVR of DAAs can allow specialists to discharge patients without co-
morbidities/side-effects once treatment is completed. Hence, General Practitioners (GPs) 
could handle the follow-up of these selected patients, leveraging also on telemedicine 
systems enabling GPs to remotely upload and share analyses with specialists as well as to 
ask for second opinions. The opportunity can thus decrease specialist’s workload by hav-
ing three follow-up visits per patient executed by GPs.
2. Reduction of in-treatment monitoring visits. Considering both significant SVR and safety 
observed for DAAs treatment as well as the expansion of access criteria, we identified the 
opportunity to skip standard monitoring visits, without generating any additional risks for 
the patient. Therefore, the specialist in charge of a given patient can decide whether to 
schedule a patient visit or not on a visit-by-visit basis, depending on his/her assessment of 
monthly laboratory tests results. The opportunity can thus decrease specialist’s workload; 
we estimate that a minimum of one and a maximum of five standard monitoring visits per 
patient will not be executed.
3. Streamlining of diagnosis visits. We noticed that a statistically significant number of pa-
tients was receiving two visits in the diagnosis phase before starting treatment; part of 
this effort was related to specialists needing to differentiate between patients meeting/not 
meeting AIFA access criteria (in place before March 2017). Thanks to new access criteria, 
the patient journey can be simplified by having a single visit including the second diagno-
sis visit and the first treatment visit.
Three additional improvement opportunities were identified, but not included in the “opti-
mized” model; we indicate them below as a reference for other healthcare providers:
 - GPs can support specialists by performing follow-up of patients affected by mild comor-
bidities. The GP would be always able to reach specialist through telemedicine systems to 
share patient’s clinical data and require a second opinion;
 - Drug distribution for DAAs is currently centralized in the Hub structure: a new process 
was designed to improve drug distribution from the Hub to each Spoke, in compliance 
with AIFA guidelines;
 - Create a task force (“Hepatitis Centre”) involving stakeholders from all relevant Depart-
ments (i.e. Gastroenterology, Infectious Disease, General Medicine) to improve efficiency 
and accuracy in disease diagnosis.
Parametric Model Design
A parametric model was designed to compare the three different organizational models 
and assess their impact on disease elimination timing, treatment capacity and direct costs. Us-
ing current treatment capacity and direct cost data collected, the parametric model simulated 
the performance of each organizational model starting from June 30th, 2016 to waiting list 
depletion.
We calculated waiting lists with month granularity, by dividing the number of untreated 
patients as of June 30th, 2016 by each organizational model’s monthly treatment capacity. 
Notably, if AIFA access criteria in place before April 1st, 2017 are considered, untreated pa-
tients correspond to previously defined as “deferred” patients; if new AIFA access criteria are 
considered, untreated patients correspond to the sum of “deferred” patients and previously de-
fined as “stand-by” patients. Newly diagnosed patients were added to the number of untreated 
patients until waiting list depletion, assuming a fixed annual increase of 5%.
Waiting list depletion was defined as the point in time (with month granularity) when the 
number of untreated patients would be equal to or below zero. Waiting list depletion was used 
as a proxy of disease elimination’s timing in the hospital’s area. Therefore, an organizational 
model with a higher treatment capacity would display a smaller waiting list, as well as a 
shorter time to waiting list depletion and disease elimination.
The parametric model was firstly used to compare CoE and Hub&Spoke considering ac-
cess criteria in place until March 30th, 2017. Secondly, the parametric model was used to com-
pare CoE and Hub&Spoke considering new AIFA access criteria. The objective of these two 
analyses was to identify the most effective and efficient model between CoE and Hub&Spoke, 
considering two alternative access scenarios. Finally, we used the parametric model to compare 
the Hub&Spoke model with the “optimized” one, considering new AIFA access criteria and 
with the objective of assessing improvement opportunities embedded in the “optimized” model.
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results
HCV Patient Journey
Three main areas were mapped: diagnosis, treatment and follow-up.
Patients have access to the hospital through three different channels: (i) referral of GPs 
or other hospital, (ii) currently inpatient moving to outpatient care in the same hospital, (iii) 
non-treated patient subject to follow-up in the same hospital.
Once a patient accesses the hospital, a first visit with the specialist is organized. The spe-
cialist verifies previous diagnosis, if any, recent laboratory analyses and prescribes additional 
lab tests. Finally, the specialist assesses the severity of the disease to decide whether to start 
the treatment or defer the patient.
Treatment length, mostly varying between 12-24 weeks, is linked to the selected therapeu-
tic scheme. Every four weeks, patient repeats lab tests, undergoes a visit with the specialist 
and collects new 28-days DAA medication.
Once treatment is completed, patient receives a follow-up program developed according 
to patient’s condition and the presence of any comorbidities; a standard follow-up includes 
three visits with the specialist 4, 12 and 24 weeks after treatment conclusion and a final fibro-
sis assessment with a Fibroscan 12 weeks after treatment conclusion.
Patient sample
Final patient sample included a total of 2,277 patients: 579 treated patients, 467 deferred 
patients and 1,231 stand-by patients.
We observed the presence of four main non-infective comorbidities related to HCV: dia-
betes (20%), ischemic cardiopathy (7%), cryoglobulinemia (6%) and hepatic insufficiency 
(3%). Co-infected HBV patients account for 17% of total study population.
If new access criteria were applied to study population, deferred patients would increase 
to 1,698 (+263%) as all stand-by patients would become part of the deferred patients group.
Direct hospital costs
Total direct hospital costs are € 1.4 M at PG-23’s Hub&Spoke model.
Direct costs for treated patients at PG-23’s Hub&Spoke model are equal to € 843,735, 
average cost for patient is € 1,479 (Table II). Specialists costs (€ 473/patient) and lab tests 
(€ 636/patient) represent key cost element of the patient journey. Other relevant direct costs 
are represented by lab technicians and director (€ 110/patient and € 102/patient, respective-
ly), nurses (€ 76/patient), Fibroscan test (€ 34/patient), pharmacists and pharmacy assistants 
(€ 25/patient and € 15/patient, respectively) and psychologists/psychiatrists (€ 8/patient).
F3 and F4 patients represented 93% of sample; F4 patients were mostly treated in 24 weeks 
whereas F3 patients in 12 weeks. 7% of the sample was composed by F1-F2 patients treated 
with DAAs due to their exceptional clinical record: they either received a liver transplant or 
were affected by severe extrahepatic diseases. Decompensated cirrhotic patients incurred the 
highest direct hospital costs (€ 1,788 vs. average cost of € 1,479) (Figure 1).
Genotype 1 was reported in 66% of patients, of which 12% was represented by patients 
with genotype 1a and 54% by patients with genotype 1b. Genotype 3 (≈ 10% of treated pa-
tients) generated the highest cost per patient (€ 1,730 versus average cost of € 1,479).
Both deferred and stand-by patients produced a yearly cost of € 351 (≈ 25% of a treated 
patient), of which more than 60% is for virologic and microbiologic laboratory tests. Overall, 
deferred and stand-by patients accounted for 41% (≈ € 597,000) of total direct hospital costs. 
In particular, deferred patients accounted for 28% of such costs (≈ € 165,000), whereas stand-
by patients represented 72% (≈ € 432,000).
Average direct costs for one patient treated in “optimized” model are reported in Table III.
Parametric Model results
We firstly compared CoE and Hub&Spoke considering AIFA limited access criteria effec-
tive until March 30th, 2017. Hub&Spoke is capable of treating a higher number (≈ +70%) of 
patients over 12 months (579 vs. 343). Waiting list is consequently shorter for Hub&Spoke: 
10 months for Hub&Spoke compared to 27 months for CoE. In terms of direct costs, cost per 
treated patient does not significantly differ between the two models (albeit it would be pos-
sible to infer that costs sustained by patients and caregivers are lower in Hub&Spoke, thanks 
to hospital proximity). We also observed a correlation between treatment capacity and cost 
efficiency: in fact, while over one year Hub&Spoke reported higher costs for treated patients 
(≈ +70%) due to the larger number of treated patients, it displayed lower costs for deferred 
patients (€ -83,000) thanks to a shorter waiting list. Cost savings of lowering the waiting list 
clearly increase over time in the Hub&Spoke model: considering the same number of patients 
will be eventually treated by both models, total direct costs down to waiting list depletion 
Diagnosis Treatment Follow-up Total
€ Hours € Hours € Hours € Hours
Specialist 105 1.7 249 4.1 119 2 473 7.8
Nurse 17  0.6 38 1.3 20 0.7 75 2.6
Fibroscan 17 - - - 17 - 34 -
Lab technician 23 0.9 49 1.9 38 1.4 110 4.2
Lab Director 8 0.3 53 0.9 41 0.7 102 1.9
Lab Test 185 - 255 - 196 - 636 -
Pharmacist - - 25 0.4 - - 25 0.4
Pharmacist Assistant - - 15 0.5 - - 15 0.5
Psychiatrist/Phycologist 2 0.1 6 0.1 - - 8 0.2
Total 357 3.5 690 9.2 431 4.8
Table ii. Average direct costs for one patient treated in Hub&Spoke model
Figure 1. Average direct costs per patient, by fibrosis score
Diagnosis Treatment Follow-up Total
€ Hours € Hours € Hours € Hours
Specialist 84 1.4 225 3.6 65 0.9 374 5.9
Nurse 15  0.5 35 1.2 8 0.3 58 2
Fibroscan  17 - - - 17 - 34 -
Lab technician  23 0.9 49  1.9  38 1.4 110 4.2
Lab Director 8  0.3 53  0.9 41 0.7 102 1.9
Lab Test 185 - 255 - 196 - 636 -
Pharmacist - - 25  0.4 - - 25 0.4
Pharmacist Assistant - - 15  0.5 - - 15 0.5
Psychiatrist/Phycologist 2 0.1 6  0.1 - - 8 0.2
Total 335 3 664 9 366 3
Table iii. Average direct costs for one patient treated in “optimized” model
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10 months for Hub&Spoke compared to 27 months for CoE. In terms of direct costs, cost per 
treated patient does not significantly differ between the two models (albeit it would be pos-
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Table iii. Average direct costs for one patient treated in “optimized” model
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equal to € 3.82 M for the CoE and € 3.58 M for the Hub&Spoke model, with the latter generat-
ing a saving of € 246,813 (Figure 2).
We secondly compared CoE and Hub&Spoke considering new AIFA access criteria. Com-
pared to the first scenario, treatment capacity remains constant in both models while waiting 
lists substantially increase due to 1,231 stand-by patients gaining access to DAA treatments. 
Waiting list for Hub&Spoke in this scenario is equal to 4.5 years, compared to 8.7 years for 
CoE. Furthermore, waiting list depletion corresponds to disease elimination as all patients are 
eligible for DAA treatment. Focusing once more on total direct costs (including both treated 
and deferred patients) down to waiting list depletion, CoE costs exceed € 8 M over nine years 
while Hub&Spoke costs are equal to € 6.2 M over the five years needed to deplete the waiting 
list (Figure 3).
Finally, we compared “optimized” and Hub&Spoke considering new AIFA access criteria. 
We observed that the implementation of optimization opportunities generated additional ben-
efits firstly in terms of treatment capacity. In fact, specialist workload would decrease by 15% 
and annual access capacity would increase by 28% (755 patients vs. 579 of Hub&Spoke). 
Thus the “optimized” model would deplete the waiting list in 2.9 years only, roughly 1.6 year 
(-35%) less than Hub&Spoke. Once again, a shorter waiting list leads to cost savings: “op-
Figure 2. CoE vs. Hub&Spoke Model in AIFA limited access criteria scenario
Figure 3. CoE vs. Hub&Spoke Model in new AIFA 2017 criteria scenario
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timized” model costs are equal to € 4.6 M over three years, showing an additional saving of 
€ 0.7 M (-13%) versus Hub&Spoke (Figure 4).
A comprehensive summary of parametric model results, considering new AIFA access 
criteria, can be found in Figure 5 and Table IV.
Figure 4. “Optimized” model vs. Hub&Spoke model in new AIFA 2017 criteria scenario
Figure 5. Parametric model results with new AIFA criteria
CoE = Center of Excellence; H&S = Hub&Spoke; Opt = optimized
aiFa criteria 2016 aiFa criteria 2017
CoE H&s CoE H&s Optimized
Direct costs (€) 495,609 843,735 495,609 843,735 789,734
 • Diagnosis 131,058 210,681 131,058 210,681 197,424
 • Treatment 225,006 399,023 225,006  399,023 383,720
 • Follow-up 139,545 234,031  139,545  234,031 208,590
Waiting lists costs (€) 247,631 164,118  680,958 596,204 583,627
Standby costs (€) 433,679 432,087 - - -
Table iV. Comparison of costs data between the three models in the two alternative scenarios
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discussion and conclusion
This study represented a first, comprehensive mapping of the HCV patient pathway in the 
Italian healthcare system. As such, it allows to specifically understand effort and cost drivers 
for all resources involved, as well as to work as a reference, baseline or benchmark for future 
studies in the field.
Key evidence from cost driver analysis is related to differences between F3, F4 com-
pensated and F4 decompensated. An average F3 patient would in fact cost about 30% less 
than an average F4 decompensated one. Costs for F1 and F2 patients from the study are not 
representative of the general population (exceptional clinical record: liver transplant or severe 
extrahepatic diseases), but it can be reasonably expected they would be even lower than aver-
age F3 patient costs.
Untreated patients (deferred, stand-by) incurred a significant share (41%) of direct costs; 
72% of such share was related to stand-by patients, mostly represented by F0-F1-F2 patients 
periodically performing visits and lab tests to monitor their disease progression. The econom-
ic impact related to the management of those patients confirms the importance of eliminating 
HCV in the early fibrosis stages, even on an economic standpoint alone, thus providing a 
further rationale for AIFA’s new access criteria.
The study also investigated the impact that different healthcare organizational models can 
have on HCV treatment, and particularly in accelerating elimination timing. We demonstrated 
how the Hub&Spoke model deployed by PG-23 was able to increase the number of patients 
treated with DAAs over twelve months (+69%) and to consequently reduce the waiting list 
(-34%) and related costs (-34%), compared to the CoE model required by Lombardy’s Health-
care System. We also demonstrated that the Hub&Spoke model can lead to successful HCV 
elimination (excluding currently undiagnosed patients) in Bergamo area within 4.5 year, com-
pared to the 8.7 years of the CoE model. Finally, we identified three optimization opportuni-
ties to improve the Hub&Spoke model; such opportunities would further reduce the waiting 
list to 2.9 years and allow additional cost savings, equal to 13% of direct costs.
Frequently, geographical differences among Italian regions led to different models and 
pathways to manage disease such as Hepatitis C, also limiting the effective introduction of 
innovative treatments [13]. Some of the optimization opportunities used to design PG-23’s 
“optimized” model can be potentially applied to other healthcare organizations at national and 
international level, regardless of them currently operating with a CoE, Hub&Spoke or a dif-
ferent organizational model. Notably, the reduction of in-treatment monitoring visits and the 
streamlining of diagnosis visits do not require a specific organizational model to be in place. 
The study helps healthcare managers going beyond regional differentiation, showing clear 
evidence of potential benefits of implementing such optimization opportunities in their own 
context, to facilitate decision-making and a wider diffusion of best practices.
Limitations to the study are mainly related to population. In line with AIFA access criteria 
in place until March 30th, 2017, study population mostly included F3-F4 patients; a limited 
number of F1-F2 patients (7% of study population) were treated with DAAs due to their 
exceptional clinical record (e.g. severe extrahepatic diseases). New access criteria are poten-
tially going to change the composition of treated population, in favor of patients with lower 
fibrosis scores. This trend points towards the implementation of different care models to bet-
ter match the needs of a wider, but less severe patient population. Care models may foresee 
further streamlining in patient pathways, for example through the elimination of mandatory 
Fibroscan tests, as DAAs are now indicated for any form of compensated liver disease regard-
less of fibrosis level [14], or also through an extended support role of GPs, in the diagnosis 
and treatment phases.
The study finally identified some areas for further investigation:
1. Launch of prevention initiatives to engage and raise disease awareness among high-risk 
patient groups;
2. Design and development of new access point network to focus on undiagnosed patients 
and facilitate early treatment.
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